Daniel Bottomly

4.8k total citations · 1 hit paper
58 papers, 1.5k citations indexed

About

Daniel Bottomly is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Daniel Bottomly has authored 58 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 30 papers in Hematology and 16 papers in Genetics. Recurrent topics in Daniel Bottomly's work include Acute Myeloid Leukemia Research (25 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Daniel Bottomly is often cited by papers focused on Acute Myeloid Leukemia Research (25 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Daniel Bottomly collaborates with scholars based in United States, India and Switzerland. Daniel Bottomly's co-authors include Shannon K. McWeeney, Beth Wilmot, Jeffrey Tyner, Robert P. Searles, Brian Druker, Robert Hitzemann, Gregory S. Yochum, Sunita Kawane, Christopher A. Eide and Priscila Darakjian and has published in prestigious journals such as New England Journal of Medicine, Nucleic Acids Research and Blood.

In The Last Decade

Daniel Bottomly

56 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML

2013 356 citations Julia E. Maxson, Anupriya Agarwal et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Bottomly United States	18	856	554	350	227	169	58	1.5k
Alec W. Gross United States	13	702 0.8×	469 0.8×	266 0.8×	286 1.3×	226 1.3×	16	1.4k
Naoki Kakazu Japan	17	852 1.0×	243 0.4×	190 0.5×	212 0.9×	265 1.6×	40	1.5k
Frederik Otzen Bagger Denmark	22	1.5k 1.8×	635 1.1×	161 0.5×	178 0.8×	248 1.5×	52	2.1k
Nikolaos Barkas United Kingdom	12	858 1.0×	316 0.6×	138 0.4×	122 0.5×	148 0.9×	22	1.3k
Jacqueline E. Payton United States	24	970 1.1×	406 0.7×	132 0.4×	105 0.5×	246 1.5×	64	1.8k
Stefan Glaser Australia	23	1.9k 2.2×	465 0.8×	192 0.5×	254 1.1×	472 2.8×	34	2.6k
Lars Velten Germany	13	1.4k 1.7×	746 1.3×	269 0.8×	116 0.5×	229 1.4×	26	2.3k
Gabriele Neu‐Yilik Germany	22	2.0k 2.3×	180 0.3×	157 0.4×	221 1.0×	84 0.5×	27	2.4k
Giovanna Marziali Italy	27	1.4k 1.7×	234 0.4×	278 0.8×	126 0.6×	289 1.7×	52	2.1k
Ellen Weersing Netherlands	15	1000 1.2×	448 0.8×	145 0.4×	297 1.3×	102 0.6×	31	1.4k

Countries citing papers authored by Daniel Bottomly

Since Specialization

Citations

This map shows the geographic impact of Daniel Bottomly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Bottomly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Bottomly more than expected).

Fields of papers citing papers by Daniel Bottomly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Bottomly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Bottomly. The network helps show where Daniel Bottomly may publish in the future.

Co-authorship network of co-authors of Daniel Bottomly

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Bottomly. A scholar is included among the top collaborators of Daniel Bottomly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Bottomly. Daniel Bottomly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eide, Christopher A., Stephen E. Kurtz, Andy Kaempf, et al.. (2025). A rapid gene expression profiler predicts tumor responsiveness and patient outcome for standard-of-care therapies in acute myeloid leukemia. Blood. 146(Supplement 1). 657–657.

Coleman, Daniel J., Joseph Estabrook, Emek Demir, et al.. (2023). Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia. Molecular Cancer Research. 21(7). 631–647. 5 indexed citations

Romine, Kyle A., et al.. (2023). Immune cell proportions correlate with clinicogenomic features and ex vivo drug responses in acute myeloid leukemia. Frontiers in Oncology. 13. 1192829–1192829. 1 indexed citations

Eide, Christopher A., Stephen E. Kurtz, Andy Kaempf, et al.. (2023). Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy. Blood Cancer Discovery. 4(6). 452–467. 12 indexed citations

Rice, William G., Stephen B. Howell, Nasrin Rastgoo, et al.. (2022). Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia. Molecular Cancer Therapeutics. 21(7). 1125–1135. 6 indexed citations

Kurtz, Stephen E., Christopher A. Eide, Andy Kaempf, et al.. (2022). Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia. Blood Advances. 6(10). 3062–3067. 6 indexed citations

Liu, Tingting, Xiaoguang Wang, Tamilla Nechiporuk, et al.. (2022). Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma. Cell Death and Disease. 13(3). 246–246. 15 indexed citations

Romine, Kyle A., Tamilla Nechiporuk, Daniel Bottomly, et al.. (2021). Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia. Blood Cancer Discovery. 2(5). 518–531. 22 indexed citations

Yenerall, Paul, Rahul K. Kollipara, Michael Peyton, et al.. (2021). Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. Cancer Research. 81(18). 4685–4695. 6 indexed citations

10.

Zhang, Haijiao, Yusuke Nakauchi, Thomas Köhnke, et al.. (2020). Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nature Cancer. 1(8). 826–839. 121 indexed citations

11.

Joshi, Sunil K., Jamie M. Keck, Christopher A. Eide, et al.. (2020). ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia. Leukemia. 34(10). 2798–2804. 11 indexed citations

12.

Damnernsawad, Alisa, Daniel Bottomly, Stephen E. Kurtz, et al.. (2020). A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia. Haematologica. 107(1). 77–85. 21 indexed citations

13.

Zhang, Haijiao, Beth Wilmot, Daniel Bottomly, et al.. (2018). Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment. Blood. 132(Supplement 1). 175–175. 23 indexed citations

14.

Zhang, Haijiao, Anna Reister Schultz, Kevin Watanabe‐Smith, et al.. (2017). Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function. Cancer Research. 77(16). 4258–4267. 10 indexed citations

15.

Khanna, Vishesh, Christopher A. Eide, Cristina E. Tognon, et al.. (2017). Recurrent cyclin D2 mutations in myeloid neoplasms. Leukemia. 31(9). 2005–2008. 10 indexed citations

16.

Maxson, Julia E., Melissa L. Abel, Jinhua Wang, et al.. (2016). Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Research. 76(1). 127–138. 26 indexed citations

17.

Maxson, Julia E., Monika A. Davare, Samuel B. Luty, et al.. (2015). Therapeutically Targetable ALK Mutations in Leukemia. Cancer Research. 75(11). 2146–2150. 17 indexed citations

18.

Bottomly, Daniel, Beth Wilmot, & Shannon K. McWeeney. (2015). plethy: management of whole body plethysmography data in R. BMC Bioinformatics. 16(1). 134–134. 1 indexed citations

19.

Bottomly, Daniel, Peter Ryabinin, Jeffrey Tyner, et al.. (2013). Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine. Genome Medicine. 5(11). 103–103. 7 indexed citations

20.

Schwartzman, Jacob, Solange Mongoue‐Tchokote, Angela Gibbs, et al.. (2011). A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. Epigenetics. 6(10). 1248–1256. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact